Instead Milestones

February 2005
Former US Secretary of Health & Human Services, Tommy Thompson, joined Instead Advisory Board.

December 2004
Postcoital Study showing Amphora effectiveness equivalent to N-9 published in Conception. Study funded by CONRAD.

July 2004
US FDA granted Instead 510k medical device clearance for Amphora to be marketed as a personal lubricant.

March 2004
US patent granted for Amphora

January2003
Rush University granted Instead exclusive worldwide rights to     Amphora.

October2001
Start of Contraceptive Efficacy Trial of BufferGel funded by NIH
BufferGel Phase 1 Safety Data published in Journal AIDS.
BufferGel Safety & Tolerability Data published in Clinical Infectious Diseases.

March 2000
BufferGel™ and Amphora-related findings presented at the first international conference devoted solely to the study of microbicides, Microbicides 2000.

Data showing BufferGel is an active spermicide in the standardized post-coital test presented at Microbicides 2000. Study funded by CONRAD.

1999
Amphora Vaginal Tolerance Data published in Conception.

October 1997
Instead filed with US FDA a Request for Designation for vaginal contraceptive application of BufferGel.

February 1996
Reprotect, LLC granted Instead, Inc. worldwide perpetual license to BufferGel applications.